Blinatumomab

Generic Name
Blinatumomab
Brand Names
Blincyto
Drug Type
Biotech
Chemical Formula
-
CAS Number
853426-35-4
Unique Ingredient Identifier
4FR53SIF3A
Background

Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker. CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since b...

Indication

Blinatumomab is indicated for the treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). It is also indicated in adults and children for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to...

Associated Conditions
Precursor B-lymphoblastic leukaemia acute, Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2018-03-26
Last Posted Date
2023-02-08
Lead Sponsor
Amgen
Target Recruit Count
121
Registration Number
NCT03476239
Locations
🇨🇳

Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

🇨🇳

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China

and more 20 locations

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

First Posted Date
2017-11-14
Last Posted Date
2024-10-17
Lead Sponsor
Amgen
Target Recruit Count
31
Registration Number
NCT03340766
Locations
🇪🇸

Research Site, Madrid, Spain

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

Phase 2
Terminated
Conditions
High-risk Diffuse Large B-cell Lymphoma
Interventions
Drug: Blinatumomab
First Posted Date
2017-10-02
Last Posted Date
2020-09-11
Lead Sponsor
Amgen
Target Recruit Count
10
Registration Number
NCT03298412
Locations
🇨🇭

Research Site, Zurich, Switzerland

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

First Posted Date
2017-08-28
Last Posted Date
2024-12-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
90
Registration Number
NCT03263572
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma

Early Phase 1
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: Blinatumomab
First Posted Date
2017-06-01
Last Posted Date
2020-02-07
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
6
Registration Number
NCT03173430
Locations
🇺🇸

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts

First Posted Date
2017-05-19
Last Posted Date
2023-08-24
Lead Sponsor
University of California, San Diego
Target Recruit Count
16
Registration Number
NCT03160079
Locations
🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

UCSF Comprehensive Cancer Center, San Francisco, California, United States

🇺🇸

UCSF Fresno Community Cancer Institute, Clovis, California, United States

and more 1 locations

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

First Posted Date
2017-05-10
Last Posted Date
2024-03-27
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
22
Registration Number
NCT03147612
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

First Posted Date
2017-04-20
Last Posted Date
2023-02-17
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
9
Registration Number
NCT03121534
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

First Posted Date
2017-04-18
Last Posted Date
2024-11-26
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
790
Registration Number
NCT03117751
Locations
🇺🇸

Children's Hospital of Michigan, Detroit, Michigan, United States

🇺🇸

St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States

🇦🇺

The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

and more 5 locations

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

First Posted Date
2017-04-14
Last Posted Date
2024-05-28
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
44
Registration Number
NCT03114865
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy